SMYD4 Antibody

What is SMYD4 and what are its key structural and functional characteristics relevant to antibody selection?

SMYD4 belongs to the class V-like SAM-binding methyltransferase superfamily and functions as a lysine methyltransferase involved in transcriptional regulation. This 804 amino acid protein (calculated molecular weight of 89 kDa) contains several functional domains that should be considered when selecting antibodies:

• Two TPR domains located at the N- and C-termini

• A MYND domain that mediates protein-protein interactions

• A SET domain that functions as a methyltransferase

SMYD4 can be detected at 85-89 kDa in Western blot applications, which aligns with its calculated molecular weight . When designing experiments, consider that SMYD4 shows different subcellular localization patterns depending on cell type - overexpressed SMYD4 appears predominantly cytoplasmic in S2 cells, while endogenous SMYD4 shows nuclear preference in the same cell line but is strongly cytoplasmic in muscle fibers .

What experimental applications are most validated for SMYD4 antibodies?

Based on the research literature and commercial antibody specifications, SMYD4 antibodies have been validated for:

For optimal results, perform antibody titration experiments when establishing a new application in your experimental system .

What common reactivity patterns should researchers expect from SMYD4 antibodies?

Available SMYD4 antibodies demonstrate the following species reactivity patterns:

• Most commercially available antibodies show reactivity with human SMYD4

• Many antibodies also react with mouse and rat SMYD4

• When studying Drosophila Smyd4 homologue, specialized antibodies have been developed

Always verify cross-reactivity experimentally when using antibodies in species other than those listed in product specifications. The high conservation of SMYD domains across species may result in cross-reactivity not explicitly tested by manufacturers .

How can researchers optimize protein-protein interaction studies involving SMYD4?

SMYD4 forms important interactions with other proteins, particularly histone deacetylases (HDACs) and PRMT5. For optimal co-immunoprecipitation experiments:

• Buffer selection: Use RIPA buffer containing 1 mM PMSF and complete protease inhibitors for cell lysis

• Technical approach:

  • For tagged proteins: Use anti-tag antibodies (anti-Flag or anti-HA) for immunoprecipitation followed by Western blotting with the reciprocal tag antibody

  • For endogenous proteins: Use SMYD4 antibody for immunoprecipitation (0.5-4μg per 200-400μg extract)

• Validation strategy: Confirm interactions through reciprocal co-IP and additional techniques such as GST pull-down assays

• Special considerations: Include appropriate negative controls (IgG, irrelevant antibody) and positive controls (known interaction partners like HDAC1 or PRMT5)

Research has demonstrated that SMYD4 interacts with PRMT5 in hepatocellular carcinoma cells, influencing methylation patterns and gene expression . In Drosophila, dSmyd4 interacts with HDAC1, HDAC3, and specifically with Ebi (a component of the SMRTER co-repressor complex) .

What methodological approaches are recommended for studying SMYD4 methyltransferase activity?

SMYD4 has been shown to monomethylate PRMT5 in hepatocellular carcinoma, affecting downstream transcriptional regulation . To study this enzymatic activity:

• Detecting methylation events:

  • Use methylation-specific antibodies (e.g., against mono-methylated lysine) in combination with SMYD4 overexpression or knockdown experiments

  • Complement antibody-based detection with mass spectrometry to identify specific methylation sites

• Functional impact assessment:

  • Use ChIP assays to examine changes in target gene promoter occupancy (e.g., PRMT5 binding and H4R3me2s/H3R2me2s marks) following SMYD4 manipulation

  • Employ luciferase reporter assays with promoters of relevant target genes (e.g., CDH1, DVL3) to confirm functional consequences

• Inhibitor studies:

  • Test the effect of specific methyltransferase inhibitors (e.g., PRMT5 inhibitor JNJ-64619178) in conjunction with SMYD4 overexpression to dissect pathway dependencies

Recent research has established that SMYD4 monomethylates PRMT5, affecting the transcription of downstream targets and forming a positive feedback loop via miR-29b-1-5p in hepatocellular carcinoma .

How should researchers approach SMYD4 antibody validation for cancers where SMYD4 shows divergent functions?

SMYD4 demonstrates context-dependent functions across different cancer types:

• Acts as an oncogene in hepatocellular carcinoma (HCC), promoting proliferation and metastasis

• Functions as a tumor suppressor in most solid tumors, with frequent downregulation observed

For proper validation in cancer studies:

• Expression level verification:

  • Include both tumor and adjacent normal tissue samples in immunoblotting or IHC experiments

  • Confirm antibody specificity using positive controls (cell lines with known SMYD4 expression) and negative controls (SMYD4 knockdown cells)

• Multi-method validation approach:

  • Correlate protein detection with mRNA expression data

  • Use multiple antibodies targeting different epitopes when possible

  • Include tissue microarrays to assess expression patterns across multiple patient samples

• Functional correlation:

  • Integrate antibody-based detection with functional readouts (e.g., proliferation, migration assays following SMYD4 manipulation)

  • Consider examining co-expression with known interaction partners (e.g., PRMT5 in HCC)

What are the most common technical challenges with SMYD4 antibodies and how can they be addressed?

Researchers working with SMYD4 antibodies may encounter several technical issues:

• Subcellular localization discrepancies:

  • SMYD4 shows different localization patterns depending on cell type and experimental conditions

  • Solution: Include proper subcellular fractionation controls and use complementary detection methods (IF and biochemical fractionation)

• Background signal:

  • Affinity purification of antibodies can reduce background. For instance, one study described purifying anti-SMYD4 using GST-MYND protein fragment immobilized on nitrocellulose

  • Solution: Optimize blocking conditions (3% nonfat dry milk in TBST has been reported for Western blot)

• Signal detection sensitivity:

  • For Western blot applications, exposure time may need optimization (60s has been reported as effective)

  • Solution: Use ECL detection systems with appropriate sensitivity for your application

• Antigen retrieval for IHC applications:

  • For paraffin-embedded samples, microwave antigen retrieval with 10 mM PBS buffer (pH 7.2) has been reported as effective

  • Solution: Compare multiple antigen retrieval methods when establishing protocols for new tissues

How can researchers distinguish between SMYD family members when studying SMYD4?

The SMYD family contains several members with similar domain structures, creating potential cross-reactivity concerns:

• Antibody selection strategy:

  • Choose antibodies raised against non-conserved regions of SMYD4

  • Immunogens containing amino acids 1-260 of human SMYD4 have been successfully used for antibody generation

• Validation approaches:

  • Include overexpression controls for SMYD4 alongside other SMYD family members

  • Use siRNA/shRNA knockdown of SMYD4 to confirm specificity

  • Include positive controls with known SMYD4 expression patterns (MCF cells have been reported)

• Gene expression correlation:

  • SMYD4 frequently shows negative correlation with other SMYD family members at the mRNA level

  • Compare protein detection with mRNA expression data when possible

What are the recommended protocols for using SMYD4 antibodies in chromatin immunoprecipitation (ChIP) studies?

While standard ChIP protocols apply to SMYD4 studies, research has revealed important considerations:

• Target selection:

  • Focus on genes known to be regulated by SMYD4-PRMT5 interaction

  • Previous studies have identified CDH1, RBL2, and DVL3 gene promoters as targets

• Antibody combination strategy:

  • Use both SMYD4 antibodies and antibodies against its interaction partners (e.g., PRMT5)

  • Include antibodies against relevant histone marks (H4R3me2s and H3R2me2s)

• Controls and validation:

  • Include SMYD4 knockdown or overexpression samples to confirm specificity

  • Verify ChIP findings with luciferase reporter assays of target gene promoters

Research has demonstrated that SMYD4 affects PRMT5 recruitment to specific gene promoters and subsequent symmetric dimethylation of H4R3 and H3R2, influencing gene expression in HCC .

How can SMYD4 antibodies be effectively used in studying the SMYD4-PRMT5 regulatory axis in cancer?

The SMYD4-PRMT5 regulatory axis represents an important oncogenic mechanism in hepatocellular carcinoma that can be studied using antibody-based approaches:

• Co-expression analysis:

  • Use immunohistochemistry to assess SMYD4 and PRMT5 co-expression in patient samples

  • High co-expression correlates with poor prognosis in HCC patients

• Functional pathway investigation:

  • Employ antibodies against SMYD4, PRMT5, and downstream targets in Western blot analysis following SMYD4 manipulation

  • Include antibodies against miR-29b-1-5p targets to investigate the positive feedback loop

• Therapeutic target assessment:

  • Study SMYD4 and PRMT5 expression following treatment with PRMT5 inhibitors

  • The PRMT5 inhibitor JNJ-64619178 effectively suppresses SMYD4's oncogenic function

Recent research has established that SMYD4 monomethylates PRMT5 and forms a positive feedback loop via miR-29b-1-5p, highlighting the SMYD4-PRMT5 axis as a potential therapeutic target for HCC treatment .

What approaches are recommended for studying the developmental role of SMYD4 with antibodies?

SMYD4 plays important roles in development, particularly in muscle tissue:

• Developmental time course analysis:

  • Use SMYD4 antibodies for Western blot or IHC analysis across developmental stages

  • In Drosophila, dSmyd4 shows expression throughout the embryonic mesoderm from stage 10, with strong expression in somatic musculature in late embryogenesis

• Tissue-specific expression:

  • Optimize IHC or IF protocols for specific tissues (muscle tissue shows strong SMYD4 expression)

  • Combine with in situ hybridization for mRNA detection to confirm specificity

• Functional studies:

  • Use tissue-specific RNAi against SMYD4 combined with antibody detection of potential interaction partners

  • In Drosophila, muscle-specific RNAi against dSmyd4 resulted in severe lethality (80% of knockdown flies could not eclose)

Studies in Drosophila have demonstrated that dSmyd4 is expressed throughout the mesoderm, with highest levels in somatic musculature, suggesting important roles in muscle development or function .

How can SMYD4 antibodies contribute to understanding the dual role of SMYD4 in different cancer types?

SMYD4 demonstrates context-dependent functions in different cancer types:

This approach can help elucidate the seemingly contradictory roles of SMYD4 across cancer types - acting as an oncogene in HCC while functioning as a tumor suppressor in most other solid tumors evaluated .

What are the recommended approaches for studying SMYD4 in relation to epigenetic regulation?

SMYD4 functions in epigenetic regulation through its methyltransferase activity and interactions with histone deacetylases:

• Histone modification analysis:

  • Use ChIP-seq with antibodies against SMYD4 and relevant histone marks following SMYD4 manipulation

  • Focus on H4R3me2s and H3R2me2s marks that are affected by the SMYD4-PRMT5 axis

• Co-repressor complex investigation:

  • Use co-immunoprecipitation with SMYD4 antibodies followed by detection of co-repressor components

  • In Drosophila, dSmyd4 interacts with HDAC1, HDAC3, and specifically with Ebi (a component of the SMRTER co-repressor complex)

• Domain-specific function:

  • Generate constructs with mutations or deletions in specific SMYD4 domains

  • Use co-IP assays to determine which domains are responsible for interactions with epigenetic partners (the MYND domain mediates interaction with HDAC1)